NEW YORK (GenomeWeb News) – MDRNA today said it has acquired the exclusive rights to develop, make, use, and sell unlocked nucleobase analog-based diagnostics from RiboTask.
The agreement expands a previous agreement between the two firms for exclusive rights to develop UsiRNA-based therapeutics. As a result of today's announcement and previously obtained exclusive rights to conformationally restricted nucleotide technology for both therapeutics and diagnostics, MDRNA now has one of the few intellectual property portfolios that support a nucleic acid-based personalized medicine platform and the ability to pursue proprietary nucleic acid-based therapeutics and diagnostics, the Bothell, Wash., firm said in a statement.
Ribotask, a privately owned Danish firm, which develops and synthesizes RNA chemistries, keeps co-exclusive right to manufacture, sell, and sublicense UNA technology for reagents development.
Financial terms of the deal were not disclosed.